The effects of insulin and insulin-like growth factors on tumor vascularization: New insights of insulin-like growth factor family in cancer

Current Medicinal Chemistry

Volumn 16, Issue 30, 2009, Pages 3931-3942

  Orciari, S ^a,b   Di Nuzzo, S ^a   Lazzarini, R ^a,b   Caprari, P ^a   Procopio, A ^a,b   Catalano, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

BM derived cells; Endothelial cells; Insulin; Insulin like growth factors; Tumor angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CP 751871; GROWTH HORMONE ANTIBODY; INSULIN; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; VASCULOTROPIN ANTIBODY;

ACCESSORY CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD VESSEL; BONE MARROW CELL; CANCER GROWTH; CANCER THERAPY; CELL METABOLISM; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; HORMONE ACTION; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; DISEASE PROGRESSION; HUMANS; INSULIN; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 70450192115     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789352268     Document Type: Review

References (109)

1. Jain, R.K.; Duda, D.G.; Clark, J.W.; Loeffler, J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol., 2006, 3, 24-40. (Pubitemid 43108832)
2. Casanovas, O.; Hicklin, D.J.; Bergers,G.; Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell., 2005, 8, 299-309. (Pubitemid 41443415)
3. Mori, M.; Saitoh, S.; Takagi, S.; Obara, F.; Ohnishi, H.; Akasaka, H.; Izumi, H.; Sakauchi, F.; Sonoda, T.; Nagata, Y.; Shimamoto, K. a review of cohort studies on the association between history of diabetes mellitus and occurrence of cancer. Asian Pacific J. Cancer Prevent., 2000, 1, 269-276.
4. Gunter, M.J.; Hoover, D.R.; Yu, H.; Wassertheil-Smoller, S.; Rohan, T.E.; Manson, J.E.; Li, J.; Ho, G.Y.; Xue, X.; Anderson, G.L.; Kaplan, R.C.; Harris, T.G.; Howard, B.V.; Wylie-Rosett, J.; Burk, R.D.; Strickler, H.D. Strickler insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst., 2009, 101, 48-60.
5. Larsson, S.C.; Orsini, N., Wolk, A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J. Natl. Cancer Inst., 2005, 97, 1679-1687. (Pubitemid 41672234)
6. Goodwin, P.J.; Ennis, M.; Pritchard, K.I.; Trudeau, M.E.; Koo, J.; Madarnas, Y.; Hartwick, W.; Hoffman, B.; Hood, N. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J. Clin. Oncol., 2002, 20, 42-51. (Pubitemid 34032594)
7. Berrino, F.; Villarini, A.; De Petris, M.; Raimondi, M.; Pasanisi, P. Adjuvant diet to improve hormonal and metabolic factors affecting breast cancer prognosis. Ann. N. Y. Acad. Sci., 2006, 1089, 110-118. (Pubitemid 47092078)
8. Pollak, M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res., 2007, 174, 49-53.
9. Jones, J.I.; Clemmons, D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 1995, 16, 3-34.
10. Bennett, A.; Wilson, D.M.; Liu, F.; Nagashima, R., Rosenfeld, R.G.; Hintz, R.L. Levels of insulin-like growth factors I and II in human cord blood. J. Clin. Endocrinol. Metab., 1983, 57, 609-612.
11. Germain-Lee, E.L.; Janicot, M.; Lammers, R.; Ullrich, A.; Casella, S.J. Expression of a type I insulin-like growth factor receptor with low affinity for insulin-like growth factor II. Biochem. J., 1992, 281, 413-417.
12. Moschos, S.J.; Mantzoros, C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology, 2002, 63, 317-332. (Pubitemid 36151524)
13. Frasca, F.; Pandini, G.; Scalia, P.; Sciacca, L.; Mineo, R.; Costantino, A.; Goldfine, ID.; Belfiore, A.; Vigneri, R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell Biol., 1999, 19, 3278-3288. (Pubitemid 29193789)
14. Samani, A.A.; Bodt, P. The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. Surg. Oncol. Clin. N. Am., 2001, 10, 289-312.
15. Dupont, J.; Pierre, A.; Froment, P.; Moreau, C. The insulin-like growth factor axis in cell cycle progression. Horm. Metab. Res., 2003, 35, 740-750. (Pubitemid 38058178)
16. Dupont, J.; Karas, M.; LeRoith, D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J. Biol. Chem., 2000, 275, 35893-35901. (Pubitemid 30841128)
17. Giorgetti, S.; Ballotti, R.; Kowalski-Chauvel, A.; Tartare, S.; Van Obberghen, E. The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J. Biol. Chem., 1993, 268, 7358-7364. (Pubitemid 23105629) (Pubitemid 23979605)
18. Hermanto, U.; Zong, C.S.; Wang, L.H. Inhibition of mitogen activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. Cell. Growth Differ., 2000, 11, 655-664.
19. Grey, A.; Chen, Q.; Xu, X.; Callon, K.; Cornish, J. Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology, 2003, 144, 4886-4893. (Pubitemid 37378403)
20. Argetsinger, L.S.; Hsu, G.W.; Myers, Jr M.G.; Billestrup, N.; White, M.F.; Carter-Su, C. Growth hormone, interferon-γ, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. J. Biol. Chem., 1995, 270, 14685-14692.
21. Lahm, H.; Amstad, P.; Wyniger, J.; Yilmaz, A.; Fischer, J.R.; Schreyer, M.; Givel, J.C. Blockade of the insulin-like growth factor 1 receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF-2-mediated autocrine loop. Int. J. Cancer, 1994, 58, 452-459.
22. Myers, Jr M.G.; Grammer, T.C.; Wang, L.M.; Sun, X.J.; Pierce, J.H.; Blenis, J.; White, M.F. Insulin receptor substrate-1 mediates phosphatidylinositol 3-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J. Biol. Chem., 1994, 269, 28783-28789. (Pubitemid 24983031) (Pubitemid 24366718)
23. Vuori, K.; Ruoslahti, E. Association of insulin receptor substrate-1 with integrins. Science, 1994, 266, 1576-1578.
24. Zong, C.S.; Zeng, L.; Jiang, Y.; Sadowski, H.B.; Wang, L.H. Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J. Biol. Chem., 1998, 273, 28065-28072
25. Keku, T.O.; Lund, P.K.; Galanko, J.; Simmons, J.G.; Woosley. J.T.; Sandler, R.S. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 2076-2081. (Pubitemid 41603248)
26. Lasko, C.M.; Bird, R.P. Modulation of aberrant crypt foci by dietary fat and caloric restriction: the effects of delayed intervention. Cancer Epidemiol. Biomarkers Prev., 1995, 4, 49-55.
27. Wrobel, G.; Roerig, P.; Kokocinski, F.; Neben, K.; Hahn, M.; Reifenberger, G.; Lichter, P. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int. J. Cancer, 2005, 114, 249-256. (Pubitemid 40194294)
28. Hartmann, W.; Koch, A.; Brune, H.; Waha, A.; Schuller, U.; Dani, I.; Denkhaus ,D.; Langmann, W.; Bode, U.; Wiestler, O.D.; Schilling, K.; Pietsch, T. Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am. J. Pathol., 2005, 166, 1153-1162 (Pubitemid 40524439)
29. Ouban, A.; Muraca, P.; Yeatman, T.; Coppola, D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol., 2003, 34, 803-808. (Pubitemid 37040618)
30. Giovannucci, E.; Pollak, M.N.; Platz, E.A.; Willett, W.C.; Stampfer, M.J.; Majeed, N.; Colditz, G.A.; Speizer, F.E.; Hankinson, S.E. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol. Biomarkers Prev., 2000, 9, 345-349. (Pubitemid 30265776)
31. Wu, X.; Tortolero-Luna, G.; Zhao, H.; Phatak, D.; Spitz, M.R.; Follen, M. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin. Cancer Res., 2003, 9, 3356-3361. (Pubitemid 37082730)
32. Figueroa, J.A.; De Raad, S.; Speights, V.O.; Rinehart, J.J. Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters. Cancer Invest., 2001, 19, 28-34.
33. Hellawell, G.O.; Turner, G.D.; Davies, D.R.; Poulsom, R.; Brewster, S.F.; Macaulay, V.M. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res., 2002, 62, 2942-2950.
34. Wilker, E.; Bol, D.; Kiguchi, K.; Rupp, T.; Beltran, L.; Di Giovanni, J. Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice. Mol. Carcinog., 1999, 25, 122-131.
35. Wilker, E.; Lu, J.; Rho, O.; Carbajal, S.; Beltran, L.; Di Giovanni, J. Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. Mol. Carcinog., 2005, 44, 137-145.
36. Hadsell, D.L.; Murphy, K.L.; Bonnette, S.G.; Reece, N.; Laucirica, R.; Rosen, J.M. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene, 2000, 19, 889-898.
37. Wang, Y.Z.; Wong, Y.C. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate, 1998, 35, 165-177.
38. Moorehead, R.A.; Hojilla, C.V.; De Belle, I.; Wood, G.A.; Fata, J.E.; Adamson, E.D.; Watson, K.L.; Edwards, D.R.; Khokha, R. Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J. Biol. Chem., 2003, 278, 50422-50427. (Pubitemid 37548886)
39. Pollak, M.; Blouin, M.J.; Zhang, J.C.; Kopchick, J.J. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br. J. Cancer, 2001, 85, 428-430.
40. Wu, Y.; Cui, K.; Miyoshi, K.; Hennighausen, L.; Green, J.E.; Setser, J.; LeRoith, D.; Yakar, S. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res., 2003, 63, 4384-4388. (Pubitemid 36951007)
41. Dunn, S.E.; Kari, F.W.; French, J.; Leininger, J.R.; Travlos, G.; Wilson, R.; Barrett, J.C. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis cell proliferation, and tumor progression in p53-deficient mice. Cancer Res., 1997, 57, 4667-4672.
42. Barozzi, C.; Ravaioli, M.; D'Errico, A.; Grazi, G.L.; Poggioli, G.; Cavrini, G.; Mazziotti, A.; Grigioni, W.F. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer, 2002, 94, 647-657.
43. Hakam, A.; Yeatman, T.J.; Lu, L.; Mora, L.; Marcet, G.; Nicosia, S.V.; Karl, R.C.; Coppola, D. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol., 1999, 30, 1128-1133. (Pubitemid 29480878)
44. Jiang, Y.; Wang, L.; Gong, W.; Wei, D.; Le, X.; Yao, J.; Ajani, J.; Abbruzzese, J.L.; Huang, S.; Xie, K. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin. Exp. Metastasis, 2004, 21, 755-764. (Pubitemid 40755015)
45. Parker, A.; Cheville, J.C.; Lohse, C.; Cerhan, J.R.; Blute, M.L. Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J. Urol., 2003, 170, 420-424. (Pubitemid 36870215)
46. Sayer, R.A.; Lancaster, J.M.; Pittman, J.; Gray, J.; Whitaker, R.; Marks, J.R.; Berchuck, A. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol. Oncol., 2005, 96, 355-361. (Pubitemid 40127134)
47. Shariat, S.F.; Kim, J.; Nguyen, C.; Wheeler, T.M.; Lerner, S.P.; Slawin, K.M. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology, 2003, 61, 359-364.
48. Miyata, Y.; Sakai, H.; Hayashi, T.; Kanetake, H. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate, 2003, 54, 125-132. (Pubitemid 36120328)
49. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer, 2003, 2, 563-572.
50. Folkman, J. Angiogenesis: An organizing principle for drug discovery? Naturalist Rev. Drug Discov., 2007, 6, 273-286.
51. Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med., 2008, 358, 2039-2049
52. Feldser, D.; Agani, F.; Iyer, N.V.; Pak, B.; Ferreira, G.; Semenza, G.L. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res., 1999, 59, 3915-3918 (Pubitemid 29393552)
53. Kim, K.W.; Bae, S.K.; Lee, O.H.; Bae, M.H.; Lee, M.J.; Park, B.C. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res., 1998, 58, 348-351. (Pubitemid 28047078)
54. Moromisato, D.Y.; Moromisato, M.Y.; Zanconato, S.; Roberts, Jr C.T. Effect of hypoxia on lung, heart, and liver insulin-like growth factor-I gene and receptor expression in the newborn rat. Crit. Care Med., 1996, 24, 919-924. (Pubitemid 26189930)
55. Bae, S.K.; Bae, M.H.; Ahn, M.Y.; Son, M.J.; Lee, Y.M.; Bae, M.K.; Lee, O.H.; Park, B.C.; Kim, K.W. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res., 1999, 59, 5989-5994. (Pubitemid 30004962)
56. Peretz, S.; Kim, C.; Rockwell, S.; Baserga, R.; Glazer, P.M. IGF1 receptor expression protects against microenvironmental stress found in the solid tumor. Radiat. Res., 2002, 158, 174-180.
57. Pandini, G.; Conte, E.; Medico, E.; Sciacca, L.; Vigneri, R.; Belfiore, A. IGF-II binding to insulin receptor isoform A induces a partially different gene expression profile from insulin binding. Ann. N.Y. Acad. Sci., 2004, 1028, 450-456. (Pubitemid 40361846)
58. Shigematsu, S.; Yamauchi, K.; Nakajima, K.; Iijima, S.; Aizawa, T.; Hashizume, K. IGF-1 regulates migration and angiogenesis of human endothelial cells. Endocr. J., 1999, 46(Suppl), 59-62. (Pubitemid 29254485)
59. Tobe, K.; Asai, S.; Matuoka, K.; Yamamoto, T.; Chida, K,; Kaburagi, Y.; Akanuma, Y.; Kuroki, T.; Takenawa, T.; Kimura, S.; Nagai, R.; Kadowaki, T. Cytoskeletal reorganization induced by insulin: involvement of Grb2/Ash, Ras and phosphatidylinositol 3-kinase signaling. Genes Cells, 2003, 8(1), 29-40. (Pubitemid 36511691)
60. Lee, O.H.; Bae, S.K.; Bae, M.H.; Lee, Y.M.; Moon, E.J.; Cha, H.J.; Kwon, Y.G.; Kim, K.W. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br. J. Cancer, 2000, 82, 385-391.
61. Clarke, K.; Smith, K.; Gullick, W.J.; Harris, A.L. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br. J. Cancer, 2001, 84, 1322-1329.
62. Kondo, T.; Vicent, D.; Suzuma, K.; Yanagisawa, M.; King, G.L.; Holzenberger, M.; Kahn, C.R. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J. Clin. Invest., 2003, 111, 1835-1842.
63. Bertolini, F.; Shaked, Y.; Mancuso, P.; Kerbel, R.S. The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification. Nat. Rev. Cancer, 2006, 6, 835-845.
64. De Palma, M.; Venneri, M.A.; Galli, R.; Sergi, L.; Politi, L.S.; Sampaolesi, M.; Naldini, L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell, 2005, 8, 211-226. (Pubitemid 41317592)
65. Conejo-Garcia, J.R.; Buckanovich, R.J.; Benencia, F.; Courreges, M.C.; Rubin, S.C.; Carroll, R.G.; Coukos, G. Vascular leukocytes contribute to tumor vascularization. Blood, 2005, 105, 679-681. (Pubitemid 40070752)
66. Humpert, P.M.; Neuwirth, R.; Battista, M.J.; Voronko, O.; von Eynatten, M.; Konrade, I.; Rudofsky, G. Jr.; Wendt, T.; Hamann, A.; Morcos, M.; Nawroth, P.P.; Bierhaus, A. SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes. Diabetes Care, 2005, 28, 934-936 (Pubitemid 40434501)
67. Hanley, M.B.; Napolitano, L.A.; McCune, J.M. Growth, hormone-induced stimulation of multilineage human hematopoiesis. Stem Cells, 2005, 23, 1170-1179.
68. Humpert, P.M.; Djuric, Z.; Zeuge, U.; Oikonomou, D.; Seregin, Y.; Laine, K.; Eckstein, V.; Nawroth, P.P.; Bierhaus, A. Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor-dependent signaling. Mol. Med., 2008, 14, 301-308. (Pubitemid 351785703)
69. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997, 275, 964-967. (Pubitemid 27087709)
70. Shaked, Y.; Ciarrocchi, A.; Franco, M.; Lee, C.R.; Man, S.; Cheung, A.M.; Hicklin, D.J.; Chaplin, D.; Foster, F.S.; Benezra, R.; Kerbel, R.S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science, 2006, 313, 1785-1787. (Pubitemid 44454154)
71. Nolan, D.J.; Ciarrocchi, A.; Mellick, A.S.; Jaggi, J.S.; Bambino, K.; Gupta, S., Heikamp, E.; McDevitt, M.R.; Scheinberg, D.A.; Benezra, R.; Mittal, V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes. Dev., 2007, 21, 1546-1558. (Pubitemid 46955726)
72. Gao, D.; Nolan, D.J.; Mellick, A.S.; Bambino, K.; McDonnell, K.; Mittal, V.; Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science, 2008, 319, 195-198.
73. Chen, Y.; Shu, H.; Ji, C.; Casinghino, S.; Kim, K., Gundberg, C.M., Centrella, M.; McCarthy, TL. Insulin-like growth factor binding proteins localize to discrete cell culture compartments in periosteal and osteoblast cultures from fetal rat bone. J. Cell Biochem., 1998, 71, 351-362. (Pubitemid 28516326)
74. Fiorelli, G.; Orlando, C.; Benvenuti, S.; Franceschelli, F.; Bianchi, S.; Pioli, P.; Tanini, A.; Serio, M., Bartucci, F.; Brandi, M.L. Characterization, regulation, and function of specific cell membrane receptors for insulin-like growth factor I on bone endothelial cells. J. Bone Miner. Res., 1994, 9, 329-337. (Pubitemid 24080570)
75. McCarthy, T.L.; Casinghino, S.; Centrella, M.; Canalis, E. Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: regulation by prostaglandin E2, growth hormone, and the insulin-like growth factors. J. Cell Physiol., 1994, 160, 163-175. (Pubitemid 24214047) (Pubitemid 24983411)
76. Hu, C.; Wu, Y.; Wan, Y.; Wang, Q.; Song, J. Introduction of hIGF-1 gene into bone marrow stromal cells and its effects on the cell's biological behaviors. Cell Transplant., 2008, 17(9), 1067-1081.
77. Moore, M.A.; Hattori, K.; Heissig, B.; Shieh, J.H.; Dias, S.; Crystal, R.G.; Rafii, S. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann. N. Y. Acad. Sci., 2001, 938, 36-45. (Pubitemid 32620016)
78. Maeng, Y.S.; Choi, H.J.; Kwon, J.Y.; Park, Y.W.; Choi, K.S.; Min, J.K.; Kim, Y.H.; Suh, P.G.; Kang, K.S.; Won, M.H.; Kim, Y.M.; Kwon, Y.G. Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCbeta2 axis. Blood, 2009, 113, 233-243.
79. Spertini, O.; Cordey, A.S.; Monai, N.; Giuffre, L.; Schapira, M. P-selectin glycoprotein ligand 1 is a ligand for L-selectin on neutrophils, monocytes, and CD34-positive hematopoietic progenitor cells. J. Cell Biol., 1996, 135, 523-531. (Pubitemid 26359344)
80. Naiyer, A.J.; Jo, D.Y.; Ahn, J.; Mohle, R.; Peichev, M.; Lam, G.; Silverstein, R.L.; Moore, M.A.; Rafii, S. Stromal derived factor-1-induced chemokinesis of cord blood CD34(+) cells (long-term culture-initiating cells) through endothelial cells is mediated by E-selectin. Blood, 1999, 94, 4011-4019.
81. Papayannopoulou, T.; Craddock, C.; Nakamoto, B.; Priestley, G.V.; Wolf, N.S. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc. Natl. Acad. Sci. USA, 1995, 92, 9647-9651.
82. Chavakis, E.; Aicher, A.; Heeschen, C.; Sasaki, K.; Kaiser, R.; El, M.N.; Urbich , C.; Peters, T.; Scharffetter-Kochanek, K.; Zeiher, A.M.; Chavakis, T.; Dimmeler, S. Role of β2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J. Exp. Med., 2005, 201, 63-72. (Pubitemid 40130084)
83. Liu, Q.; Ning, W.; Dantzer, R.; Freund, G.G.; Kelley, K.W. Activation of protein kinase C-zeta and phosphatidylinositol 3′-kinase and promotion of macrophage differentiation by insulin-like growth factor-I. J. Immunol., 1998, 160, 1393-13401.
84. Chang, C.; Werb, Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol., 2001, 11, 37-43. (Pubitemid 33001442) (Pubitemid 33713169)
85. Saikali, Z.; Setya, H.; Singh, G.; Persad, S. Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells. Cancer Cell Int., 2008, 3, 8-10.
86. Rorive, S.; Berton, A.; D'haene, N.; Takacs, CN.; Debeir, O.; Decaestecker, C.; Salmon, I. Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas. Glia, 2008, 56, 1679-1690.
87. Chen, L.; Tredget, E.E.; Wu, P.Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE, 2008, 3,1886.
88. Lapidot T.; Dar, A.; Kollet, O. How do stem cells find their way home? Blood, 2005, 106, 1901-1910. (Pubitemid 41291700)
89. Haider, H.K.H.; Jiang, S., Idris, N.M., Ashraf, M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ. Res., 2008, 103, 1300-1308
90. Li, Y.; Yu, X.; Lin, S.; Li, X.; Zhang, S.; Song, Y.H. Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. Biochem. Biophys. Res. Commun., 2007, 356, 780-784. (Pubitemid 46499034)
91. Asahara, T.; Takahashi, T.; Masuda, H.; Kalka, C.; Chen, D.; Iwaguro, H.; Inai, Y.; Silver, M.; Isner, J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J., 1999, 18, 3964-3972. (Pubitemid 29335849)
92. Smadja, D.M.; Bièche, I.; Susen, S.; Mauge, L.; Laurendeau, I.; d'Audigier, C.; Grelac, F.; Emmerich, J.; Aiach, M.; Gaussem, P. Interleukin 8 is differently expressed and modulated by PAR-1 activation in early and late endothelial progenitor cells. J. Cell Mol. Med., 2008, in press.
93. Kooijman, R.; Himpe, E.; Potikanond, S.; Coppens, A. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines. Growth Horm. IGF Res., 2007, 17, 383-391. (Pubitemid 47324303)
94. Wang, C.H.; Ting, M.K.; Verma, S.; Kuo, L.T., Yang, N.I.; Hsieh, I.C.; Wang, S.Y.; Hung, A.; Cherng, W.J. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am. Heart J., 2006, 152, 1051.e1-8
95. Mendez-Ferrer, S.; Lucas, D.; Battista, M.; Frenette, P.S. Haematopoietic stem cell release is regulated by circadian oscillations. Nature, 2008, 452, 442-447.
96. Fraser, W. D.; Ahmad, A. M.; Vora, J. P. The physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis. Curr. Opin. Nephrol. Hypertens., 2004, 13, 437-444.
97. Moser, C.; Schachtschneider, P.; Lang, S.A.; Gaumann, A.; Mori, A.; Zimmermann, J.; Schlitt, H.J.; Geissler, E.K.; Stoeltzing, O. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur. J. Cancer, 2008, 44, 1577-1586.
98. Letsch, M.; Schally, A.V., Busto, R.; Bajo, A.M.; Varga, J.L. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 1250-1255. (Pubitemid 36183988)
99. Goya, M.; Miyamoto, S.; Nagai, K.; Ohki, Y.; Nakamura, K.; Shitara, K.; Maeda, H.; Sangai, T.; Kodama, K.; Endoh, Y.; Ishii, G.; Hasebe, T.; Yonou, H.; Hatano, T.; Ogawa, Y.; Ochiai, A. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res., 2004, 64, 6252-6258. (Pubitemid 39129428)
100. O'Gorman, D.B.; Weiss, J.; Hettiaratchi, A.; Firth, S.M.; Scott, C.D. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology, 2002, 143, 4287-4294.
101. Lee, H.Y.; Chun, K.H.; Liu, B.; Wiehle, S.A.; Cristiano, R.J.; Hong, W.K.; Cohen, P.; Kurie, J.M. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res., 2002, 62, 3530-3537. (Pubitemid 34651404)
102. Samani, A.A.; Chevet, E.; Fallavollita, L.; Galipeau, J.; Brodt, P. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res., 2004, 64, 3380-3385. (Pubitemid 38657908)
103. Cohen, B.D.; Baker, D.A.; Soderstrom, C.; Tkalcevic, G.; Rossi, A.M.; Miller, P.E.; Tengowski, M.W.; Wang, F.; Gualberto, A.; Beebe, J.S.; Moyer, J.D. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res., 2005, 11, 2063-2073.
104. Hewish, M.; Chau, I.; Cunningham, D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anticancer Drug Discov., 2009, 4, 54-72.
105. Hofmann, F.; Garcia-Echeverria, C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug. Discov. Today, 2005, 10, 1041-1047. (Pubitemid 41074142)
106. Tao, Y.; Pinzi, V.; Bourhis, J.; Deutsch, E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat. Clin. Pract. Oncol., 2007, 4, 591-602. (Pubitemid 47534758)
107. Bertolini, F.; Paul, S.; Mancuso, P.; Monestiroli, S.; Gobbi, A.; Shaked, Y.; Kerbel, R.S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res., 2003, 63, 4342-4346.
108. Fürstenberger, G.; von Moos, R.; Lucas, R.; Thürlimann, B.; Senn, H.J.; Hamacher, J.; Boneberg, E.M. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer, 2006, 94, 524-531. (Pubitemid 43289756)
109. Bertolini, F. Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells. Cancer Metastasis Rev., 2008, 27, 95-101.